Physician profile
Melissa Moore
NPI 1336571298
$1,591.48
in general payments reported to CMS, 2019-2025
22 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $280 · 2023: $240 · 2024: $203 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $236.59 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.27 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $175.17 | 2021-2025 | Airsupra, Farxiga, Lokelma |
| Pfizer INC. | $125.29 | 2021-2025 | |
| Abbvie INC. | $107.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $97.37 | 2023-2025 | |
| Lilly USA, LLC | $87.61 | 2021-2023 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $76.42 | 2021-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $71.62 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $65.19 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.50 | 2021-2024 | Xifaxan |
| Novo Nordisk INC | $51.57 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $42.49 | 2025 | |
| Alexion Pharmaceuticals, INC. | $40.77 | 2021-2022 | |
| Evoke Pharma, INC. | $34.81 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.57 | 2024-2025 | Caplyta |
| Agios Pharmaceuticals, INC. | $18.54 | 2025 | Pyrukynd |
| Kowa Pharmaceuticals America, INC. | $17.82 | 2023 | Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2022 | |
| Baxter Healthcare | $15.00 | 2024 | Hillrom - Monarch Airway Clearance System |
| Takeda Pharmaceuticals U.S.A., INC. | $12.20 | 2021 | |
| Genentech USA, INC. | $10.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.